PML down-regulation in soft tissue sarcomas

Journal of Cellular Physiology

Volumn 224, Issue 3, 2010, Pages 644-648

  Vincenzi, Bruno ^a   Perrone, Giuseppe ^a   Santini, Daniele ^a   Grosso, Federica ^b   Silletta, Marianna ^a   Frezza, Annamaria ^a   Rossi, Sabrina ^c   Russo, Antonio ^d   Rabitti, Carla ^a   Gebbia, Nicola ^d   Badalamenti, Giuseppe ^d   Casali, Paolo ^b   Muda, Andrea Onetti ^a   Tos, Angelo Paolo Dei ^c   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c GENERAL HOSPITAL   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAXX PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN C JUN; PROTEIN P105; PROTEIN P53; RETINOIC ACID RECEPTOR ALPHA;

ANGIOGENESIS; ANGIOSARCOMA; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL AGING; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 15; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GERM CELL TUMOR; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG TUMOR; MYOFIBROBLASTIC SARCOMA; MYXOSARCOMA; ONSET AGE; PLEOMORPHIC SARCOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SARCOMA; SOFT TISSUE SARCOMA; SURVIVAL RATE; SYNOVIAL SARCOMA; TUMOR SUPPRESSOR GENE;

DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; SARCOMA; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77954614219     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22161     Document Type: Article

References (32)

1. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP. 2006. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442:779-785.
2. Bernassola F, Oberst A, Melino G, Pandolfi PP. 2005. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene 24:6982-6986.
3. Choi YH, Bernardi R, Pandolfi PP, Benveniste EN. 2006. The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc Natl Acad Sci USA 103:18715-18720.
4. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. 2001. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J 20:4547-4559.
5. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558-561.
6. Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F, Pelicci PG. 1998. Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16:2905-2913.
7. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S. 1997. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 90:4046-4053.
8. Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP, Jr., Sinkovics JG, Rivkin SE, Brownlee R, Frei E III. 1972. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30:1632-1638.
9. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96:269-279.
10. Halazonetis TD, Gorgoulis VG, Bartek J. 2008. An oncogene-induced DNA damage model for cancer development. Science 319:1352-1355.
11. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK. 2009. SEER Cancer Statistics Review, 1975-2006. Bethesda: National Cancer Institute.
12. Kakizuka A, Miller WH, Jr., Umesono K, Warrell RP, Jr., Frankel SR, Murty VV, Dmitrovsky E, Evans RM. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663-674.
13. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Zhong S, Pandolfi PP, Ishii S. 2001. PMLR-ARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb. J Biol Chem 276:43491-43494.
14. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, Juhlin L, Degos L, Calvo F, de The H. 1995. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10:1315-1324.
15. Kurki S, Latonen L, Laiho M. 2003. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci 116:3917-3925. (Pubitemid 37279307)
16. Lee HE, Jee CD, Kim MA, Lee HS, Lee YM, Lee BL, Kim WH. 2007. Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett 247:103-109.
17. Lin HK, Bergmann S, Pandolfi PP. 2004. Cytoplasmic PML function in TGF-beta signalling. Nature 431:205-211.
18. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY. 2007. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25:3144-3150. (Pubitemid 47218064)
19. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, Droge W, Will H, Schmitz ML. 2003. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63:4310-4314. (Pubitemid 36950995)
20. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207-210.
21. Salomoni P, Khelifi AF. 2006. DAXX: Death or survival protein? Trends Cell Biol 16: 97-104.
22. Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP. 2005. The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 105:3686-3690.
23. Salomoni P, Ferguson BJ, Wyllie AH, Rich T. 2008. New insights into the role of PML in tumour suppression. Cell Res 18:622-640. (Pubitemid 351793118)
24. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya-Feldstein J, Tempst P, Pandolfi PP. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269-283.
25. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol Cell 24:331-339.
26. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. 2006. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441:523-527.
27. Vincenzi B, Santini D, Perrone G, Russo A, Adamo V, Rizzo S, Castri F, Antinori A, Alloni R, Crucitti PF, Morini S, Rabitti C, Vecchio FM, Magistrelli P, Coppola R, Tonini G. 2009. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients. Ann Oncol 20:78-83.
28. Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann TG, Schwanitz G, Hoischen C, Maul G, Dittrich P, Hemmerich P. 2008. Dynamics of component exchange at PML nuclear bodies. J Cell Sci 121:2731-2743.
29. WHO. 2002. Soft tissue sarcoma. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer. pp. 193-197.
30. Ye X, Zerlanko B, Kennedy A, Banumathy G, Zhang R, Adams PD. 2007a. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell 27:183-196. (Pubitemid 47058300)
31. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, Adams PD. 2007b. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 27:2452-2465. (Pubitemid 46581338)
32. Zhu J, Lallemand-Breitenbach V, de The H. 2001. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20:7257-7265. (Pubitemid 33107375)